Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

LAMPIT 30 MG COMPRIMIDOS - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/LAMPIT 30 MG COMPRIMIDOS

Approved

STANDARD

LAMPIT 30 MG COMPRIMIDOS

Bayer Hispania S.L.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Jun 4, 2024
Approval ID: 1e08f3ffc55fa327
Company: Bayer Hispania S.L.
Type: Standard

Approval Details

Approval Id: 1e08f3ffc55fa327
Drug Cima Aemps Name: LAMPIT 30 MG COMPRIMIDOS
Register Number: 89507
Holder Company Name: Bayer Hispania S.L.
Marketing Company Name: Bayer Hispania S.L.
Authorization Date: 2024-06-04
Dosage Form: COMPRIMIDO
Dose: 30 mg
Route Of Administration: VÍA ORAL
Prescription Type: Diagnóstico Hospitalario
Commercialized: Yes
Company Name: Bayer Hispania S.L.

Active Ingredients

NIFURTIMOX

30 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Jun 4, 2024

Approval ID

1e08f3ffc55fa327

Type

Standard

Back to CIMA-AEMPS Approvals